MPP’s 20262030 strategy builds on 15 years of experience to ensure that health innovations reach people in LMICs sooner, more equitably and more sustainably. By combining public health-oriented licensing, technology transfer and strong partnerships, MPP will continue to turn innovation into access, and access into impact.
Our mission is to increase equitable access to innovative medicines and other health technologies through public health-oriented voluntary licensing and technology transfer.
A world in which people in need in low- and middle- income countries (LMICs) have rapid, secure and sustainable access to effective and affordable medical treatments and health technologies.
Recent crises have exposed the fragility of global health systems, while nearly two billion people in low- and middle-income countries (LMICs) still lack access to essential medicines. Funding pressures, health emergencies, rising non-communicable disease (NCD) burdens and concentrated supply chains continue to strain systems and budgets. At the same time, emerging health products and technologies, stronger regional manufacturing efforts and new global frameworks such as the WHO Pandemic Agreement, are creating important opportunities to advance more equitable and secure access to health products in LMICs.
Between 2010-2030,
will have been supplied in LMICs thanks to MPP’s public health oriented voluntary licensing and technology transfer
MPP’s 2026-2030 strategy builds on 15 years of experience to ensure that health innovations reach people in LMICs sooner, more equitably and more sustainably.
Our work is defined not just by what we do, but by the principles that guide how we do it.
With billions of doses of treatments supplied through access-oriented voluntary licensing since 2010, MPP’s work has had tremendous impact.